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Abstract
Background: Anti-Mu¨llerian hormone (AMH) is a product of growing ovarian follicles. The concentration
of AMH in blood may also reflect the non-growing follicle (NGF) population, i.e. the ovarian reserve,
and be of value in predicting reproductive lifespan. A full description of AMH production up to the
menopause has not been reported.
Methodology/Principal Findings: By searching the published literature for AMH concentrations in healthy
pre-menopausal females, and using our own data (combined n = 3, 260) we have generated and robustly
validated the first model of AMH concentration from conception to menopause. This model shows that
34% of the variation in AMH is due to age alone. We have shown that AMH peaks at age 24.5 years,
followed by a decline to the menopause. We have also shown that there is a neonatal peak and a potential
pre-pubertal peak. Our model allows us to generate normative data at all ages.
Conclusions/Significance: These data highlight key inflection points in ovarian follicle dynamics. This first
validated model of circulating AMH in healthy females describes a transition period in early adulthood,
after which AMH reflects the progressive loss of the NGF pool. The existence of a neonatal increase
in gonadal activity is confirmed for females. An improved understanding of the relationship between
circulating AMH and age will lead more accurate assessment of ovarian reserve for the individual woman.
Author Summary
Women are born with their full compliment of immature eggs, that declines with increasing age to the
menopause at an average age of 50 years. There is currently no accepted test that will reliably predict
how many immature eggs remain for an individual woman (their ovarian reserve). This is of particular
importance to young women who may be at risk of a premature menopause after cancer treatment or
who may be considering assisted reproduction. Serum anti-Mu¨llerian hormone (AMH) is produced by
cells that surround the developing and maturing eggs. The measurement of serum AMH is currently
used by many clinicians as a surrogate measure of ovarian reserve. However, little is known about how
reliably AMH reflects ovarian reserve and activity for the individual woman. In this study, using out
own data and data previously published from many sources in healthy women, we have provided the
first rigorously validated model of AMH from conception to menopause. We have shown for the first
time that AMH peaks at age 24.5 years, followed by a decline to the menopause when it is undetectable.
This model allows us to generate normal range values for AMH from birth to menopause. An improved
understanding of the relationship between circulating AMH and age will allow clinicians to more reliably
assess ovarian reserve, and ultimately allow women to plan their own reproductive course with confidence.
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2Introduction
The human ovary establishes its complete complement of primordial follicles during fetal life, with re-
cruitment and thereby depletion of this dormant primordial follicle pool required for normal fertility but
ultimately leading to reproductive senescence [1]. Primordial follicles are recruited continuously from
before birth to join the early growing cohort (initial recruitment). After puberty, at every new cycle a
limited number of follicles are recruited from this cohort of small growing follicles (cyclic recruitment),
followed by a final selection for dominance and ovulation of a single follicle [2, 3]. Thus, at any specific
time, the majority of primordial follicles are held in a dormant state, and when eventually recruited most
will not reach the preovulatory stage but are destined to be removed through atresia at earlier stages
of follicular development. Currently, clinical assessment is unable to assess the number of primordial
follicles, or their rate of loss/activation. Knowledge of these aspects of ovarian function would be of value
in a range of contexts, both clinical and social/personal, as well as being of great value in promoting our
understanding of how reproductive lifespan is regulated.
Anti-Mu¨llerian hormone (AMH), is now recognized as a principal regulator of early follicular re-
cruitment from the primordial pool [4, 5], with AMH null mice demonstrating accelerated depletion of
primordial follicle number and an almost three-fold increase in smaller growing follicles [6]. Further-
more this increase in number of growing follicles occurs despite lower serum follicle stimulating hormone
(FSH) concentrations [7], suggesting that in the absence of AMH, follicles are more sensitive to FSH and
progress through the early stages of follicular development. AMH is produced by small growing but not
primordial follicles [8–10], although limited data suggest that serum AMH concentrations also correlate
with primordial follicle number in humans [11] as in rodents [12]. The prepubertal endocrine environ-
ment is markedly different from the adult with low and non-cyclical gonadotropins: the relevance of this
to AMH secretion is incompletely understood although follicle growth through the preantral stages and
occasionally to early antral stages (i.e. across the full range of stages that secrete AMH) is observed in
childhood [13]. A recent study has reported an increase in initial primordial follicular recruitment rates
up to the age of puberty, and then a progressive decline to the menopause [14]. This suggests that AMH
concentrations at any given age in both childhood and adulthood may mirror primordial follicular re-
cruitment rates, rather than simply primordial follicle number. Consequently across the female lifespan,
circulating AMH will potentially exhibit an initial increase followed by a non-linear decline as is well
established for the primordial follicle pool [14–18].
In keeping with this, AMH concentrations in adults have been shown to decline with age [19, 20].
AMH concentrations are relatively stable across the menstrual cycle [21, 22] and also between cycles in
the same woman [23]. Measurement of AMH is increasingly used in the prediction of ovarian response to
superovulation [24]. Although large AMH cohort studies describing falling AMH concentrations in adult
women (mostly from populations attending infertility clinics) have recently been published [25–28], the
data for AMH concentrations in children have until recently been considerably more limited [29, 30]. To
date no single study has examined AMH across the lifespan in healthy females. The aim of the current
study is to produce a model of serum AMH in healthy females from conception to the menopause.
Results
The validated model
Data from published studies and our own (Table 1) were used to derive the model (Figure 1). This
included 3,260 data points across the age range from -0.3 (cord blood from preterm infants) to 54.3 years
(Table 2). After 10-fold stratified cross-validation, the model with the highest coefficient of determination
(r2) was a degree 20 polynomial of the form
3Figure 1. Serum AMH data The red line is the model that best fits the 3,260 datapoints shown as
triangles. The coefficient of determination, r2, is 0.34, indicating that 34% of variation in serum AMH
concentrations is due to age alone. Peak serum AMH is at 24.5 years.
log10(AMH + 1) = c0 + c1age + c2age
2 + . . . + c20age
20
with coefficients cj given in Table 3.
This model has an r2 of 0.34, indicating that roughly one third of variation in AMH concentrations is
due to age alone, with the remaining two thirds of the variation being due to other factors. Serum AMH
peaks at 24.5 years on average, with concentrations decreasing shortly after birth, and again between
eight and twelve years of age.
Validation
For each of the 10 folds of the validation process, the highest ranked of 215 models was a polynomial
similar to the model reported above: in every case the returned coefficients, r2 and peaks were similar
(Table 4). Moreover, the average training error was within 1% of the average cross-validation estimate of
the prediction error across 10 folds (Table 4). We therefore consider that the model derived for all 3,260
datapoints generalises well to unseen data, and hence report this as a validated model for serum AMH
concentrations in the normal female population (Figure 2).
4Discussion
We have generated the first validated model of serum AMH in the healthy human population from
conception to menopausal ages. Our model shows that serum AMH concentrations peak at age 24.5
years for the average case, and suggests that two thirds of the variation in AMH concentrations for
healthy females is due to factors other than age.
We have shown that serum AMH falls shortly after birth, with concentrations only increasing again
after about two years of age. This feature is in line with evidence of a mini-puberty seen in neonatal
girls [31,32], although more clearly characterized in boys [33], and with a recent longitudinal study of AMH
in female neonatal blood [29] (the data from which were included in our study). Our model also shows
that serum AMH concentration falls between the ages of eight and twelve, before rising to a peak in the
mid-twenties. This fall may be an artefact of our model derivation process rather than a true reproductive
biological event. As the fall coincides with the initial increases in gonadotropin concentrations of early
puberty, it is possible that it reflects changes in the proportions of follicles at different stages of growth
with increasing numbers progressing to antral stages rather than becoming atretic early on [3]. AMH
is produced by early growing follicles at all stages up to the early antral stage [8] but it is unknown
which follicle class contributes most to circulating concentrations. The rising granulosa cell mass (and
thus AMH production per follicle) will be balanced by progressively declining numbers of follicles at each
stage of growth [2, 3].
Our incomplete understanding of how early follicle recruitment and growth are regulated means that
any such interpretation is speculative but our results both suggest this avenue of future research, and
give useful indications of effect sizes and ages for the design of such investigations.
The increase in AMH during the postnatal period, supported by a recent longitudinal analysis in the
first 3 months of life [29], is likely to be analogous to the well established transient rise in testosterone and
inhibin B in boys at that time [33]. This is likely to reflect the relatively high gonadotrophin concentrations
that are present which will support more advanced follicle development than occurs in the remainder of
the prepubertal period. Consistent with this, the ovary shows follicle growth to the early antral stage
from birth [13]. The continuing rise in AMH through childhood is striking, and parallels rising follicle
growth initiation from the very large pool at these ages [14]. The rising AMH production would therefore
act to limit follicle growth activation [5, 6], thus a point of inflection when follicle recruitment starts to
slow, and which is followed by a decline in AMH concentrations is predictable: our data demonstrate the
age at which this occurs.
Our observed increase in AMH concentrations beyond the age of 12 years, is in contrast to the recent
analysis by Hagen et al. which suggested in a cross-sectional study that AMH did not change from age
8 to age 25 or indeed relative to pubertal stage [29]. Censoring our own data between these two ages
would also suggest that AMH does not vary markedly, however, this would lose the power of the broader
picture afforded by the entire age range analysis performed here. The lack of an increase beyond age
12 as suggested by Hagen et al., is in marked contrast to current and previous studies, which have all
suggested a peak in early adulthood. A recent analysis of 9,601 infertility patients [25] and a smaller
study of 82 healthy subjects both report that AMH concentrations decrease after age 20 [19]. Although
two studies have reported peak AMH at age 31-33 [34,35], these were substantially smaller incorporating
144 and 58 subjects and the minimum age was 14 years and 25 years respectively. This smaller sample
size and lack of data from younger (especially neonatal) subjects may have skewed the reported peaks
towards a higher age.
We recognize that although our study has a number of limitations – including the accuracy of the
health status of subjects in the studies used and the dependence on accurate graphical presentation of
published results – it also has considerable strengths. The dataset was derived from over 3,500 subjects
with ages ranging from minus 0.3 years to 68 years, the model was then validated using standard mathe-
matical techniques, with very good generalisation to unseen data for each of the 10 cross-validation steps.
We did not make any presumptions regarding the optimal fitting model, yet the optimal model exhib-
5ited a non-linear decline in AMH in adult life consistent with previous cross-sectional and longitudinal
studies [25, 34, 36, 37], and the minipuberty seen in neonatal girls [29, 31, 32]. This validated model can
therefore be used to accurately interpret concentrations of serum AMH in females across the lifespan.
The model is based entirely on cross-sectional data (the small amount of longitudinal data was treated as
if cross-sectional). Further longitudinal validation in similarly large populations will provide additional
confirmation.
It should be noted that our methodological choices have no effect on the qualitative nature of our
results. If we convert to DSL values instead of IBC, do not add one to the log-adjusted values for ease
of exposition, do not censor at age 54.3, allow models with more parameters (or restrict to models with
slightly fewer parameters), use k× 2 or bootstrap cross-validation, we still obtain a validated model with
similar peaks, r2 and level of generalisation to unseen data. The current introduction of the GenII AMH
assay (Beckman Coulter) uses the same standards as the IBC assay, thus we anticipate that the normative
model presented (Figure 2) will be valid for values obtained using that system.
Figure 2. The normal range for serum AMH in girls and women The red line is the
log-unadjusted validated AMH model using IBC assay values. The blue and green lines are the 68% and
95% prediction limits for the model (plus and minus one and two standard deviations respectively).
This comprehensive statistical analysis of 3,260 healthy infants, children and women has facilitated the
first validated normative model of age related circulating AMH from conception to the menopause. The
model provides a means for interpretation of how an individual’s serum AMH concentration compares
with population norms.
6Materials and Methods
Data acquisition
Table 1. Serum AMH data summary
Ref. 1st Author Data Assay n Average age Age range Det. lim. Intra CV Inter CV
[35] Soto Graph IBC 58 30.3 (mean) ±8.7 SD 0.10 5.3 8.7
[38] Guibourdenche Graph IBC 192 NS -0.3 – 1.0 0.30 5.3 8.7
[39] Hudecova Graph IBC 64 46.3 (mean) ±6.4 SD 0.70 12.3 12.3
[40] Mulders Graph IBC 82 29.9 19.6 – 35.6 NS 5.0 8.0
[41] Pastor Graph IBC 42 NS 18.0 – 50.0 0.10 5.3 7.8
[42] Piltonen Graph IBC 44 31.6 (mean) 21.0 – 44.0 NS 5.1 6.6
[20] van Rooij Graph IBC 162 NS 25.0 – 46.0 0.05 5.0 8.0
[43] Laven Graph IBC 41 NS 20.0 – 36.0 0.05 5.0 8.0
[19] de Vet Graph IBC 82 29.0 ±4.0 SD 0.05 5.0 8.0
[44] Knauf Graph IBC 83 34.2 (mean) ±3.4 SD 0.03 11.0 11.0
[45] Lee Graph IBC 225 NS 0.0 – 51.0 0.50 9.0 15.0
[36] La Marca Graph IBC 24 44.0 (mean) ±2.8 SD 0.24 5.0 8.0
[29] Hagen Graph IBC 891 NS 0.0–68.0 0.03 7.8 11.6
[46] van Beek Graph DSL 82 29.0 20.0 – 35.0 NS 5.0 15.0
[47] Sanders Graph DSL 43 24.1 (mean) 0.1 – 51.0 0.01 NS 11.4
[34] van Disseldorp Graph DSL 144 37.9 (mean) 25.0 – 46.0 0.03 11.0 11.0
[48] Tehrani Graph DSL 267 27.1 16.0 – 44.0 0.01 5.2 9.1
[49] Dorgan Graph DSL 204 44.7 (mean) 33.3 – 54.7 0.06 8.0 8.0
[30] Ahmed Raw DSL 128 8.5 0.5 – 16.5 0.50 8.0 8.0
[25] Nelson Raw DSL 441 36.1 21.9 – 47.8 0.03 3.4 8.6
Total IBC 1,990 15.8 -0.3 – 68.0
Total DSL 1,309 35.4 0.2 – 54.7
Total n 3,299 34.0 -0.3 – 68.0
Censored total n 3,260 28.3 -0.3 – 54.3
The references relate to the bibliography section of this paper. Age information is given as median and
range, or as mean and standard devation (SD), depending on which form was reported in the referenced
study. Detection limits are given in ng/ml. Intra- and inter-observer coefficients of variation (CV) are
percentages. NS denotes not stated. The CVs are indications of the likely accuracy of repeated
measurements being performed either by the same observer (intra), or by another observer with similar
training (inter). For longitudinal studies – [19,29,40,48] – we report the average age of participants at
first measurement. The censored total excludes any values greater than 54.3 years (i.e. one standard
deviation above the average age at menopause).
Studies involving serum AMH measurements of human females were identified by performing PubMed
and Medline searches and searching individual journals (including Menopause, Fertility and Sterility,
Human Reproduction and the Journal of Clinical Endocrinology and Metabolism) using the search terms
AMH, Mu¨llerian inhibiting substance, ovarian reserve and polycystic ovarian syndrome. The references
of included studies (Table One; [19,20,29,34–36,38–49]) were checked to identify further relevant studies
to be processed. Data was selected for this analysis only for subjects who were not known to be infertile,
or have an identified chronic illness. Hence all subjects were either in control groups from controlled
studies or from prospective studies of the healthy population. Any data from subjects with a chronic
disease or undergoing infertility assessment or investigation were excluded from the study. In the main,
the data was from pre-menopausal women. In three studies the menopausal status of the women was
not stated [45, 47, 49]. Data from fetal blood (n = 25) and cord blood (n = 53) of infants [38] were
included. Longitudinal data – from [19, 29, 40, 48] – were recorded as cross-sectional values. The data
were extracted from graphs using Plot Digitizer software [50] to convert datapoints on the graphs into
7numerical data. Repeated datapoints were isolated by requiring that the acquired dataset matched the
descriptive statistics provided in the supporting paper (Table One).
We combined the resulting dataset with two sets of raw Scottish data. The first consisted of individual
serum AMH measurements (n=441, median age 36.1 years, max. age 47.8, min age 21.9) from a cohort
of women whose partners were known to have severe male factor infertility requiring ICSI, and where no
other female cause of infertility had been identified [25]. Individual patient serum AMH measurements
were undertaken between July 2006 and October 2009 in the biochemical laboratories of the University
of Glasgow, the Glasgow Centre for Reproductive Medicine and the Glasgow Royal Infirmary. All three
facilities were providing centralised AMH testing for infertility clinics within the United Kingdom. Ethical
approval for studies involving these data was obtained from NHS Scotland. Subjects were informed that
data may be analysed anonymously. Individual ethical approval has not been taken for studies involving
this data, as it is routine anonymous clinical data which is covered by the general UK National Health
Service ethics for analysis of routine biochemical data, provided it is anonymous, The second dataset
was supplied by Ahmed et al. [30] and consists of 128 measurements taken from subjects aged 0.5 – 16.5
years.
Table 2. Sample sizes at each age for the AMH model
Age (yrs) n Age (yrs) n Age (yrs) n Age (yrs) n Age (yrs) n Age (yrs) n
≤ 0 144
0 277 10 61 20 21 30 77 40 79 50 25
1 43 11 69 21 37 31 77 41 72 51 18
2 12 12 65 22 27 32 101 42 80 52 19
3 12 13 61 23 35 33 74 43 66 > 53 12
4 14 14 82 24 32 34 97 44 58
5 14 15 61 25 50 35 84 45 59
6 51 16 37 26 36 36 116 46 36
7 60 17 64 27 55 37 98 47 37
8 60 18 40 28 67 38 100 48 37
9 58 19 40 29 45 39 86 49 23
The 3,260 AMH datapoints described in Table 1, split into ages. n denotes the size of the subset of the
data associated with an age in years.
Serum AMH values were standardised to give AMH measurements in ng/ml using the conversion
formula 1 pmol/l = 7.143 ng/ml.
The resulting data were considered separately depending on the assay used to obtain serum AMH
values. The first dataset (n=1,990, median age 15.8 years, max. age 68.0, min age -0.3) came from those
studies in which the serum concentrations of AMH were determined using enzyme-linked immunoassay
kits IBC (Immunotech Beckman Coulter Company, France). The second dataset (n=1,309, median age
35.4 years, max. age 54.7, min age 0.2) came from studies in which the enzyme-immunometric assay
Active MIS/AMH ELISA kits DSL (Diagnostic Systems Laboratories Inc., TX, USA) were used. We
converted the DSL data into IBC values using the conversion formula
2.02 ∗DSL = IBC
which has a reported r2 of 0.85 [51], and censored 39 datapoints over 54.3 years (mean age at menopause
plus one standard deviation [52].) The resulting dataset consists of 3,260 serum AMH concentrations at
known ages, and approximates circulating AMH concentrations in the healthy population from conception
to menopause.
8Data analysis
Stratified 10-fold cross-validation was performed using standard techniques [53]. The dataset was split
into 10 distinct subsets, k0, . . . , k9, of nearly equal size, each with similar mean, median, minimum and
maximum. For fold i, ki was retained as test data, with the remaining 90% of the data used for training
purposes. For each training set we added zero AMH values at conception, in order to force models through
the only known AMH concentration at any age. Since variability increases with AMH concentration, we
log-adjusted the data (after adding one to each value so that zero AMH on a chart represents zero serum
AMH). All data were analysed as cross-sectional values (i.e. longitudinal patterns were not considered).
We then fitted 215 mathematical models to the i-th test data using TableCurve-2D (Systat Software
Inc., San Jose, California, USA), and ranked the results by coefficient of determination, r2. Each model
defines a generic type of curve and has parameters which, when instantiated gives a specific curve of
that type. For each model we calculated values for the parameters that maximise the r2 coefficient.
The Levenberg-Marquardt non-linear curve-fitting algorithm was used throughout, with convergence to 5
significant figures after a maximum of 1,000 iterations. The highest ranked model was chosen as the best
model for the test data, and the mean square error and r2 were calculated after removing the artificial
zero values at conception.
Table 3. 10-fold cross-validation models
k0 k1 k2 k3 k4 k5 k6 k7 k8 k9 All data
c0 2.70e-01 2.67e-01 2.67e-01 2.67e-01 2.72e-01 2.69e-01 2.67e-01 2.71e-01 2.70e-01 2.68e-01 2.69e-01
c1 2.78e-01 2.91e-01 2.91e-01 2.75e-01 2.84e-01 2.83e-01 2.62e-01 2.50e-01 2.79e-01 2.69e-01 2.77e-01
c2 -1.92e-01 -1.90e-01 -1.90e-01 -1.91e-01 -1.98e-01 -1.78e-01 -1.87e-01 -1.91e-01 -1.86e-01 -1.74e-01 -1.88e-01
c3 -3.21e-02 -4.82e-02 -4.82e-02 -3.27e-02 -3.59e-02 -3.42e-02 -1.54e-02 -2.93e-04 -2.95e-02 -1.66e-02 -2.99e-02
c4 7.17e-02 8.45e-02 8.45e-02 7.22e-02 7.92e-02 6.39e-02 5.99e-02 4.72e-02 6.64e-02 5.14e-02 6.85e-02
c5 -3.13e-02 -3.62e-02 -3.62e-02 -3.14e-02 -3.52e-02 -2.64e-02 -2.78e-02 -2.23e-02 -2.86e-02 -2.27e-02 -3.00e-02
c6 7.56e-03 8.71e-03 8.71e-03 7.57e-03 8.66e-03 6.14e-03 6.98e-03 5.53e-03 6.85e-03 5.55e-03 7.25e-03
c7 -1.21e-03 -1.38e-03 -1.38e-03 -1.20e-03 -1.40e-03 -9.56e-04 -1.15e-03 -8.98e-04 -1.09e-03 -9.02e-04 -1.16e-03
c8 1.38e-04 1.57e-04 1.57e-04 1.37e-04 1.61e-04 1.07e-04 1.35e-04 1.03e-04 1.23e-04 1.05e-04 1.33e-04
c9 -1.17e-05 -1.31e-05 -1.31e-05 -1.15e-05 -1.36e-05 -8.90e-06 -1.16e-05 -8.83e-06 -1.04e-05 -9.08e-06 -1.12e-05
c10 7.50e-07 8.35e-07 8.35e-07 7.33e-07 8.75e-07 5.66e-07 7.61e-07 5.72e-07 6.64e-07 5.97e-07 7.20e-07
c11 -3.71e-08 -4.08e-08 -4.08e-08 -3.60e-08 -4.31e-08 -2.78e-08 -3.83e-08 -2.85e-08 -3.28e-08 -3.02e-08 -3.56e-08
c12 1.43e-09 1.55e-09 1.55e-09 1.38e-09 1.65e-09 1.06e-09 1.49e-09 1.10e-09 1.26e-09 1.19e-09 1.37e-09
c13 -4.27e-11 -4.57e-11 -4.57e-11 -4.09e-11 -4.89e-11 -3.16e-11 -4.50e-11 -3.30e-11 -3.78e-11 -3.63e-11 -4.08e-11
c14 9.89e-13 1.05e-12 1.05e-12 9.41e-13 1.12e-12 7.31e-13 1.05e-12 7.68e-13 8.76e-13 8.56e-13 9.44e-13
c15 -1.76e-14 -1.83e-14 -1.83e-14 -1.66e-14 -1.98e-14 -1.29e-14 -1.88e-14 -1.37e-14 -1.56e-14 -1.55e-14 -1.67e-14
c16 2.34e-16 2.41e-16 2.41e-16 2.21e-16 2.61e-16 1.72e-16 2.52e-16 1.83e-16 2.09e-16 2.10e-16 2.23e-16
c17 -2.27e-18 -2.31e-18 -2.31e-18 -2.13e-18 -2.51e-18 -1.67e-18 -2.46e-18 -1.78e-18 -2.03e-18 -2.06e-18 -2.16e-18
c18 1.51e-20 1.52e-20 1.52e-20 1.41e-20 1.65e-20 1.11e-20 1.64e-20 1.19e-20 1.36e-20 1.39e-20 1.43e-20
c19 -6.16e-23 -6.12e-23 -6.12e-23 -5.74e-23 -6.66e-23 -4.54e-23 -6.74e-23 -4.84e-23 -5.55e-23 -5.75e-23 -5.83e-23
c20 1.16e-25 1.14e-25 1.14e-25 1.08e-25 1.24e-25 8.56e-26 1.27e-25 9.14e-26 1.05e-25 1.10e-25 1.10e-25
The columns are the 21 coefficients cj for the degree 20 polynomial returned by TableCurve2D that
gave the highest r2 for the dataset under consideration. For fold ki, the dataset consisted of all points
except the ki test data. After validation of the degree 20 polynomial (Table 3), its coefficients were
calculated for the entire dataset (final column). We report this model as our validated model of serum
AMH from conception to menopause.
For validation purposes, the mean square error of the ki data for the i-th model was calculated and
compared to the mean square error of training data for the same model. In other words, the cross-
validation estimate of the prediction error of the model was compared to the training error of the model.
Training error is expected to be underestimated (due to overfitting of the chosen data) and the cross-
validation estimate of the prediction error is expected to be overestimated (due to underfitting of unseen
data). We consider a model to be validated if the differences between these errors is small.
9For each fold the highest ranked model was a degree 20 polynomial of the form
log10(AMH + 1) = c0 + c1age + c2age
2 + . . . + c20age
20
Hence, after validation, the 21 parameters for this model were derived for the entire dataset (n = 3,260),
again using TableCurve2D. The resulting model is reported as our validated model (Table 2).
Table 4. 10-fold cross-validation results
k0 k1 k2 k3 k4 k5 k6 k7 k8 k9 Mean
MSE train 0.069 0.068 0.067 0.069 0.069 0.069 0.069 0.069 0.069 0.068 0.069
MSE test 0.064 0.070 0.080 0.065 0.068 0.069 0.067 0.068 0.064 0.078 0.069
r2 0.338 0.338 0.341 0.352 0.343 0.339 0.341 0.340 0.337 0.345 0.341
Age at peak AMH 25.1 21.7 21.5 22.0 25.5 24.5 24.6 24.5 24.1 25.0 23.8
The mean squared error (MSE) for the model with highest r2 is given for both the training set (90% of
the dataset) and the test set (the remaining 10%) for each of the ten folds. Since – both for individual
folds and on average – the errors are similar, we consider the model to be validated. The r2 and peak
ages are for the highest ranked model returned by TableCurve2D for each fold.
Acknowledgments
References
1. Broekmans FJ, Soules MR, Fauser BC (2009) Ovarian aging: mechanisms and clinical conse-
quences. Endocrine Reviews 30: 465–493.
2. Gougeon A (1996) Regulation of ovarian follicular development in primates: facts and hypotheses.
Endocrine Reviews 17: 121–155.
3. McGee EA, Hsueh AJ (2000) Initial and cyclic recruitment of ovarian follicles. Endocrine Reviews
21: 200–214.
4. Durlinger AL, Visser JA, Themmen AP (2002) Regulation of ovarian function: the role of anti-
Mu¨llerian hormone. Reproduction 124: 601–609.
5. Gigli I, Cushman RA, Wahl CM, Fortune JE (2005) Evidence for a role for anti-Mullerian hormone
in the suppression of follicle activation in mouse ovaries and bovine ovarian cortex grafted beneath
the chick chorioallantoic membrane. Molecular Reproductive Development 71: 480–488.
6. Durlinger AL, Kramer P, Karels B, de Jong FH, Uilenbroek JT, et al. (1999) Control of primordial
follicle recruitment by anti-Mu¨llerian hormone in the mouse ovary. Endocrinology 140: 5789–5796.
7. Durlinger AL, Gruijters MJ, Kramer P, Karels B, Kumar TR, et al. (2001) Anti-Mu¨llerian hormone
attenuates the effects of FSH on follicle development in the mouse ovary. Endocrinology 142: 4891–
4899.
8. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, et al. (2004) Anti-Mu¨llerian
hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle
recruitment. Molecular Human Reproduction 10: 77–83.
10
9. Bezard J, Vigier B, Tran D, Mauleon P, Josso N (1987) Immunocytochemical study of anti-
Mu¨llerian hormone in sheep ovarian follicles during fetal and post-natal development. Journal
of Reproduction and Fertility 80: 509–516.
10. Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, van Leeuwen EC, et al. (1995) Anti-
mu¨llerian hormone and anti-mu¨llerian hormone type II receptor messenger ribonucleic acid ex-
pression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced
follicle growth. Endocrinology 136: 4951–4962.
11. Hansen KR, Hodnett GM, Knowlton N, Craig LB (2011) Correlation of ovarian reserve tests with
histologically determined primordial follicle number. Fertility & Sterility 95: 170–175.
12. Kevenaar ME, Meerasahib MF, Kramer P, van de Lang-Born BM, de Jong FH, et al. (2006) Serum
anti-mu¨llerian hormone levels reflect the size of the primordial follicle pool in mice. Endocrinology
147: 3228–3234.
13. Lintern-Moore S, Peters H, Moore GP, Faber M (1974) Follicular development in the infant human
ovary. Journal of Reproduction and Fertility 39: 53–64.
14. Wallace WHB, Kelsey TW (2010) Human ovarian reserve from conception to the menopause. PLoS
ONE 5: e8772.
15. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF (1992) Accelerated disappearance
of ovarian follicles in mid-life: implications for forecasting menopause. Human Reproduction 7:
1342–1346.
16. Faddy MJ, Gosden RG (1996) A model conforming the decline in follicle numbers to the age of
menopause in women. Human Reproduction 11: 1484–1486.
17. Faddy MJ (2000) Follicle dynamics during ovarian ageing. Molecular & Cellular Endocrinology
163: 43–48.
18. Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR, et al. (2008) A new model of
reproductive aging: the decline in ovarian non-growing follicle number from birth to menopause.
Human Reproduction 23: 699-708.
19. de Vet A, Laven J, De Jong F, Themmen APN, Fauser BCJM (2002) Antimu¨llerian hormone serum
levels: a putative marker for ovarian aging. Fertility & Sterility 77: 357–362.
20. van Rooij IAJ, Broekmans FJM, Scheffer GJ, Looman CWN, Habbema JDF, et al. (2005) Serum
antimu¨llerian hormone levels best reflect the reproductive decline with age in normal women with
proven fertility: a longitudinal study. Fertility & Sterility 83: 979–87.
21. Cook CL, Siow Y, Taylor S, Fallat ME (2000) Serum mu¨llerian-inhibiting substance levels during
normal menstrual cycles. Fertility & Sterility 73: 859–861.
22. La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, et al. (2004) Anti-Mu¨llerian hormone
plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation.
Human Reproduction 19: 2738–2741.
23. Fanchin R, Taieb J, Lozano DH, Ducot B, Frydman R, et al. (2005) High reproducibility of serum
anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens
its role in the assessment of ovarian follicular status. Human Reproduction 20: 923–927.
11
24. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, et al. (2010) Anti-Mullerian hormone
(AMH) as a predictive marker in assisted reproductive technology (ART). Human Reproduction
Update 16: 113–130.
25. Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A (2011) Nomogram for the
decline in serum antimu¨llerian hormone: a population study of 9,601 infertility patients. Fertility
& Sterility 95: 736–741.
26. Nelson SM, Messow MC, McConnachie A, Wallace WHB, Kelsey TW, et al. (2011) External
validation of nomogram for the decline in serum anti-Mu¨llerian hormone in women: a population
study of 15,834 infertility patients. Reproductive BioMedicine Online (published online 20 May
2011).
27. Seifer DB, Baker VL, Leader B (2011) Age-specific serum anti-Mu¨llerian hormone values for 17,120
women presenting to fertility centers within the United States. Fertility & Sterility 95: 747–750.
28. Almog B, Shehata F, Suissa S, Holzer H, Shalom-Paz E, et al. (2011) Age-related normograms
of serum antimu¨llerian hormone levels in a population of infertile women: a multicenter study.
Fertility & Sterility (published online 20 May 2011).
29. Hagen CP, Aksglaede L, Sorensen K, Main KM, Boas M, et al. (2010) Serum levels of anti-Mu¨llerian
hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172
Turner syndrome patients. Journal of Clinical Endocrinology & Metababolism 95: 5003–5010.
30. Ahmed SF, Keir L, McNeilly J, Galloway P, O’Toole S, et al. (2010) The concordance between serum
anti-Mu¨llerian hormone and testosterone concentrations depends on duration of hCG stimulation
in boys undergoing investigation of gonadal function. Clinical Endocrinology 72: 814–9.
31. Lee MM (2003) Reproductive hormones in infant girls–a harbinger of adult reproductive function?
Journal of Clinical Endocrinology & Metabolism 88: 3513–3514.
32. Chellakooty M, Schmidt IM, Haavisto AM, Boisen KA, Damgaard IN, et al. (2003) Inhibin A,
inhibin B, follicle-stimulating hormone, luteinizing hormone, estradiol, and sex hormone-binding
globulin levels in 473 healthy infant girls. Journal of Clinical Endocrinology & Metabolism 88:
3515–3520.
33. Andersson AM, Toppari J, Haavisto AM, Petersen JH, Simell T, et al. (1998) Longitudinal repro-
ductive hormone profiles in infants: peak of inhibin B levels in infant boys exceeds levels in adult
men. Journal of Clinical Endocrinology & Metabolism 83: 675–681.
34. van Disseldorp J, Faddy MJ, Themmen aPN, de Jong FH, Peeters PHM, et al. (2008) Rela-
tionship of serum antimu¨llerian hormone concentration to age at menopause. Journal of Clinical
Endocrinology & Metabolism 93: 2129–34.
35. Soto N, In˜iguez G, Lo´pez P, Larenas G, Mujica V, et al. (2009) Anti-Mu¨llerian hormone and inhibin
B levels as markers of premature ovarian aging and transition to menopause in type 1 diabetes
mellitus. Human Reproduction 24: 2838–44.
36. La Marca A, De Leo V, Giulini S, Orvieto R, Malmusi S, et al. (2005) Anti-Mu¨llerian hormone
in premenopausal women and after spontaneous or surgically induced menopause. Journal of the
Society for Gynecologic Investigation 12: 545–8.
37. Sowers M, McConnell D, Gast K, Zheng H, Nan B, et al. (2010) Anti-Mu¨llerian hormone and
inhibin B variability during normal menstrual cycles. Fertility & Sterility 94: 1482–1486.
12
38. Guibourdenche J, Lucidarme N, Chevenne D, Rigal O, Nicolas M, et al. (2003) Anti-Mu¨llerian
hormone levels in serum from human foetuses and children: pattern and clinical interest. Molecular
and Cellular Endocrinology 211: 55–63.
39. Hudecova M, Holte J, Olovsson M, Sundstro¨m Poromaa I (2009) Long-term follow-up of patients
with polycystic ovary syndrome: reproductive outcome and ovarian reserve. Human Reproduction
24: 1176–83.
40. Mulders AGMGJ, Laven JSE, Eijkemans MJC, de Jong FH, Themmen APN, et al. (2004) Changes
in anti-Mu¨llerian hormone serum concentrations over time suggest delayed ovarian ageing in nor-
mogonadotrophic anovulatory infertility. Human Reproduction 19: 2036–42.
41. Pastor CL, Vanderhoof VH, Lim LCL, Calis KA, Premkumar A, et al. (2005) Pilot study in-
vestigating the age-related decline in ovarian function of regularly menstruating normal women.
Fertility & Sterility 84: 1462–9.
42. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, et al. (2005) Serum anti-
Mu¨llerian hormone levels remain high until late reproductive age and decrease during metformin
therapy in women with polycystic ovary syndrome. Human Reproduction 20: 1820–6.
43. Laven JSE (2004) Anti-Mu¨llerian Hormone Serum Concentrations in Normoovulatory and Anovu-
latory Women of Reproductive Age. Journal of Clinical Endocrinology & Metabolism 89: 318–323.
44. Knauff EaH, Eijkemans MJC, Lambalk CB, ten Kate-Booij MJ, Hoek A, et al. (2009) Anti-
Mu¨llerian hormone, inhibin B, and antral follicle count in young women with ovarian failure.
Journal of Clinical Endocrinology & Metabolism 94: 786–92.
45. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist GB, et al. (1996) Mu¨llerian inhibiting
substance in humans: normal levels from infancy to adulthood. Journal of Clinical Endocrinology
& Metabolism 81: 571–6.
46. van Beek RD, van den Heuvel-Eibrink MM, Laven JSE, de Jong FH, Themmen APN, et al.
(2007) Anti-Mu¨llerian hormone is a sensitive serum marker for gonadal function in women treated
for Hodgkin’s lymphoma during childhood. Journal of Clinical Endocrinology & Metabolism 92:
3869–74.
47. Sanders RD, Spencer JB, Epstein MP, Pollak SV, Vardhana PA, et al. (2009) Biomarkers of ovarian
function in girls and women with classic galactosemia. Fertility & Sterility 92: 344–51.
48. Tehrani FR, Solaymani-Dodaran M, Hedayati M, Azizi F (2010) Is polycystic ovary syndrome an
exception for reproductive aging? Human Reproduction 25: 1775–1781.
49. Dorgan JF, Stanczyk FZ, Egleston BL, Kahle LL, Shaw CM, et al. (2009) Prospective case-control
study of serum mu¨llerian inhibiting substance and breast cancer risk. Journal of the National
Cancer Institute 101: 1501–9.
50. Huwaldt J (2005). Plot Digitizer. http://plotdigitizer.sourceforge.net/.
51. Hehenkamp WJK, Looman CWN, Themmen APN, de Jong FH, Te Velde ER, et al. (2006) Anti-
Mu¨llerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation.
Journal of Clinical Endocrinology & Metabolism 91: 4057–63.
52. Treloar AE (1981) Menstrual cyclicity and the pre-menopause. Maturitas 3: 249–264.
53. Hastie T, Tibshirani R, Friedman JH (2001) The elements of statistical learning: data mining,
inference, and prediction. New York: Springer-Verlag, 533 pp.
